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Background: Current studies on salvage radiotherapy (sRT) investigate timing, dose-escalation and anti-hormonal
treatment (ADT) for recurrent prostate cancer. These approaches could either be limited by radiation-related susceptibility
of the anastomosis or by suspected side-effects of long-term ADT. A phase II protocol was developed to investigate the
benefit and tolerability of regional hyperthermia with moderately dose-escalated radiotherapy.
Methods: The study hypothesis is that radio-thermotherapy is a safe and feasible salvage treatment modality. The primary
endpoint is safety measured by frequency of grade 3+ genitourinary (GU) and gastrointestinal (GI) adverse events
(AE) according to Common Toxicity Criteria (CTC) version 4. Feasibility is defined by number of hyperthermia treatments
(n≥ 7) and feasibility of radiotherapy according to protocol. Target volume delineation is performed according to the
EORTC guidelines. Radiation treatment is administered with single doses of 2 Gy 5×/week to a total dose of
70 Gy. Regional hyperthermia is given 2×/week to a total of 10 treatments.
Results: European centres participate in the phase II trial using intensity modulated RT (IMRT) or volumetric
modulated arc technique (VMAT). The initiating centres were participants of the SAKK 09/10 study, where the
same patient criteria and target volume definition (mandatory successful performed dummy run) were applied
insuring a high standardisation of the study procedures.
Conclusions: The introduced phase II study implements highly precise image-guided radiotherapy and regional
hyperthermia. If the phase II study is found to be safe and feasible, a multicenter phase III study is planned to test
whether the addition of regional hyperthermia to dose-intensified sRT improves biochemical control.
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Salvage radiotherapy for biochemical recurrence after
prostatectomy
Approximately 15–40 % of patients experience a biochem-
ical relapse after radical prostatectomy within 5 years [1, 2].
Salvage radiotherapy (sRT) improves cancer-specific sur-
vival in these patients compared to observation alone [3].
Therefore, early salvage treatment at PSA levels below
0.5 ng/ml is recommended by European guidelines [4] to
ensure a benefit for more than half the patients [5, 6]. In* Correspondence: arndt-christian.mueller@med.uni-tuebingen.de
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creativecommons.org/publicdomain/zero/1.0/addition, a short prostate-specific antigen doubling
time of <6 months is prognostic for metastasis suggest-
ing only little benefit of sRT [7]. A steep sigmoidal
dose–response curve was detected in the radiation dose
range between 60–70 Gy. Current dose escalation from
60 to 70 Gy would increase biochemical control by ap-
proximately 20 %, indicating that dose-escalation is
beneficial for these patients [6].Recruiting and unpublished randomized studies on
salvage radiotherapy
Ongoing and/or up to now unpublished randomized
studies on sRT to the prostatic fossa investigate timing [8],
dose-escalation [9] and anti-hormonal treatment (ADT)ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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risk of potentially increased morbidity, either due to radi-
ation susceptibility of the anastomosis, or due to pharmaco-
logical side effects related to long-term ADT. The first
analysis of toxicity from the dose-escalation trial comparing
64 Gy with 70 Gy demonstrated no significant differences
between both dose levels with regard to GU and GI acute
toxicity scored with CTCAE version 4 [12]. Therefore,
further treatment intensification is reasonable and
might be performed without or with acceptable in-
creased side effects.Rationale for this trial
Regional hyperthermia is successfully applied as a re-
sponse modifier with radiotherapy, leading to im-
proved local control in different tumour entities
including rectal cancer [13–16], gynaecologic malig-
nancies [16–18], sarcoma [19, 20] and others. In pros-
tate cancer, radio-thermotherapy also increased local
tumour control in advanced disease with low toxicity
rates [21–27]. Quality of life was not affected by regional
hyperthermia [27]. According to a recently performed
estimation, addition of hyperthermia to radiotherapy in
prostate cancer would result in a dose-escalation
equivalent to at least 10 Gy [28]. Consequently, appli-
cation of regional hyperthermia could be a method to
avoid radiation-based dose-escalation above 70 Gy and
to circumvent ADT-related toxicity in prostate cancer
patients after surgery.
There is limited experience with radio-thermotherapy
as a salvage modality in prostate cancer [23] and a
phase II protocol with an interim safety analysis was
therefore developed. The phase II study investigates the
potential benefit and tolerability of hyperthermia with
moderately dose-escalated salvage radiotherapy to a
total dose of 70 Gy in biochemically recurred prostate
cancer after prostatectomy.Fig. 1 Design of the phase II study of radio-thermotherapy for biochemicaMethods and design
Study design
The study is designed as a multicentre prospective phase II
study. An outline of the study procedures is given in Fig. 1.
Study hypothesis
The study hypothesis is that radio-thermotherapy is a
safe and feasible salvage treatment modality.
Primary endpoint
The primary endpoint is safety measured by frequency of
grade 3+ genitourinary (GU) and gastrointestinal (GI)
adverse events (AE) according to CTCAE version 4 [29].
Feasibility is defined as the number of hyperthermia treat-
ments (n ≥ 7) and feasibility of radiotherapy according to
protocol in ≥ 95 % of patients.
Secondary endpoints
1. Quality of life (QoL) assessment
2. Biochemical progression-free survival defined as
PSA-rise > 0.4 ng/ml or increasing PSA-level where
the initial PSA-level is above 0.4 ng/ml.
3. Clinical progression-free survival.
4. Time without ADT, i.e., time until initiation of ADT.
Assessment of QoL
Quality of life (QoL) assessment using the EORTC
QLQ-C30 [30], the QLQ-PR25 [31] and the Memorial
Anxiety Scale for Prostate Cancer (MAX-PC) [32] ques-
tionnaires is performed at 3, 12, 24, and 36 months.
Inclusion criteria
Patients with the following characteristics will be eligible
for this study.
1. Lymph node negative adenocarcinoma of the
prostate treated with radical prostatectomy at leastl recurrent prostate cancer
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pT2a-3b, R0-1, pN0 or cN0 according to the UICC
TNM 2009; Gleason score available.
2. PSA progression after prostatectomy defined as two
consecutive rises with the final PSA > 0.1 ng/ml or
three consecutive rises. The first value must be
measured at least 4 weeks after radical
prostatectomy.
3. PSA at randomization ≤ 2 ng/ml.
4. No evidence of macroscopic local recurrence or
metastatic disease on pre-sRT-MRI (magnetic
resonance imaging; with i.v. contrast) or pre-sRT-CT
(multislice computed tomography with i.v. and oral
contrast) of the abdomen and pelvis assessed within
16 weeks prior to randomization.
5. WHO performance status 0–1 at randomization.
6. Age at randomization between 18 and 80 years.
7. Informed consent.
Exclusion criteria
Patients with the following characteristics will be ineli-
gible for this study.
1. Persistent PSA value 4–20 weeks after radical
prostatectomy > 0.4 ng/ml.
2. Palpable mass in the prostatic fossa, unless histology
proves no evidence of recurrence.
3. Pelvic lymph node enlargement >1 cm in short axis
diameter of the abdomen and pelvis (cN1), unless
the enlarged lymph node is sampled and negative.
4. Presence or history of bone metastases. Bone scan is
mandatory in cases of clinical suspicion (e.g., bone
pain).
5. Other malignancies within five years before planned
sRT; non-melanoma skin cancers are allowed.
6. ADT or bilateral orchiectomy.
7. Previous pelvic radiotherapy.
8. Hip prosthesis.
9. Metal clusters/markers and patients with a
pacemaker.
10. Severe or active co-morbidities impairing the
feasibility of hyperthermia or dose intensified sRT
including (but not exclusively limited to):Table 1 Constraints for organs at risk (OARs) in the phase II
study on radio-thermotherapy for biochemical recurrent
prostate cancer
Organs at risk (OARs) Constraints
V50 V60 V65 V70
Rectal wall n.a. ≤50% n.a. ≤20%
Bladder wall n.a. n.a. ≤50% n.a.
Femoral heads ≤10% n.a. n.a. n.a.
n.a. not applicable, OAR organs at risk, V organ volume receiving a specified dose– chronic inflammatory bowel disease
– acute bacterial or fungal infection requiring
intravenous antibiotics at the time of
randomization
– unstable angina pectoris and/or congestive heart
failure requiring hospitalization within the last
6 months
– transmural myocardial infarction within the last
6 months
– chronic obstructive pulmonary disease
exacerbation or other respiratory disordersrequiring hospitalization or precluding planned
treatment within the study at the time of
randomization
– psychiatric disorder precluding understanding of
information on trial-related topics, giving informed
consent or filling out QoL questionnaires
11. Concurrent treatment with other experimental
drugs or other anti-cancer therapy; treatment in a
clinical trial within 30 days prior to trial entry.Radiation treatment planning
Patients will be placed in the supine position with a com-
fortably filled bladder and empty rectum. The use of an
endorectal balloon is allowed. Target volume definition will
be performed in accordance with the European organisa-
tion for research and treatment of cancer (EORTC) guide-
lines [33]. Organs at risk (OAR) include bladder, rectum
and femoral heads. The bladder wall (BW) and rectal wall
(RW) are contoured using a 5 mm internal margin. Con-
straints for OAR are given in Table 1.
The definition of volumes and dose reporting will be
in accordance with the International Commission on
Radiation Units and Measurements (ICRU) Report 83 [34].
A modified treatment concept can be used in cases
of clear identification of regions of risk (i.e., distinct
localization of pT3a-region, R1-region, bed of seminal
vesicles for pT3b-stages). In such cases, the standard
target volume (EORTC-definition) will be treated to a
total dose of 66.5 Gy (5 × 1.9 Gy/week) and the target
volume for regions of risk (modified integrated boost
volume) will be irradiated with 5 × 2.0 Gy/week to a
total dose of 70.0 Gy.Salvage radiotherapy delivery
SRT is administered to a total dose of 70 Gy (35 fractions
with single fractions of 2 Gy) over 7 weeks (modified treat-
ment concept [see above] with reduced dose to the
EORTC-target volume of 5x1.9 Gy/week to 66.5 Gy and an
in integrated boost with 5x2.0 Gy/week to 70 Gy in regions
with high risk of recurrence). SRT should be delivered once
daily except at weekends. Intensity modulated RT (IMRT)
or alternatively rotational techniques such as Rapidarc,
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(VMAT) will be eligible.
Concurrent hyperthermia
Regional hyperthermia will be carried out within 2
(max. within 4) hours after radiation treatment twice a
week. Multichannel thermometry probes or MR-mapping
temperature probes will be placed into the rectum and ur-
ethra/bladder and the thermal target temperature will be at
least 41 °C for 60 min (maximum temperature: 43 °C). The
total hyperthermia time is approximately 90 min including
an induction period of 30 min. Ten hyperthermia sessions
will be conducted. Hyperthermia should start in the first
week of radiation treatment (see schedule in Fig. 1).
Suboptimal hyperthermia sessions (time duration or
temperature) are counted as hyperthermia session and
will not be repeated. Due to any reason omitted hyperther-
mia sessions can be performed until the last fraction of
radiation treatment. The interval between hyperthermia ap-
plications should be at least 48 h. Hyperthermia will be per-
formed according to current guidelines [35, 36].
Trial duration and follow-up assessment
The trial is planned to be initiated in summer 2015. The
recruitment period of the entire study (100 patients) will
take approximately 36 months. The primary endpoint of
the study (acute toxicity) can be evaluated three months
later. The follow-up period is three years. The whole
study duration is estimated to be 75 months if the study
is not terminated early (see criteria for termination).
Follow-up visits are scheduled at 3 months after the end
of treatment and 6-monthly thereafter, until the third
year. Assessment includes overall survival, PSA-level,
clinical recurrence-free survival with regard to local, re-
gional and distant control. Time without treatment for
prostate cancer and toxicity according to CTCAE 4.0
will be evaluated. QoL will be assessed at 3, 12, 24,
36 months after completion of treatment.
Sample size calculation and criteria for termination of the
study
The H0-hypothesis of the protocol is that ≥20 % of patients
experience grade 3+ genitourinary and gastrointestinal
acute toxicities (CTC v 4.0) or ≥30 % in case of pre-existing
G2-toxicities.
Accordingly, the study is terminated if ≥20 % of pa-
tients (n = 10/50) experience grade 3+ genitourinary and
gastrointestinal acute toxicities (CTC v 4.0) or ≥30 % in
case of pre-existing G2-toxicities. If toxicity is below the
mentioned threshold, the study will be continued to in-
clude 100 patients treated per protocol. In the final ana-
lysis (n = 100), the H0-hypothesis is rejected if ≤13 %
(13/100) grade 3+ genitourinary and gastrointestinal
acute toxicities (CTC v 4.0) were observed. This study(Simon’s design) has a significance level p < 0.05 and a
power of 87.2 % if G3 + −toxicity is ≤10 %.
Ethical and legal considerations
This study will be conducted in accordance with the
guidelines of the local ethics committees. The protocol,
patient information and informed consent sheets were
submitted to the independent Ethics Committee of the
Medical Faculty, University of Berlin, Germany and are
submitted to the Ethics Committee of the Medical Fac-
ulty, University of Tuebingen, Germany. The “Independ-
ent Expert Committee of the DEGRO” stated that the
dose range of 64–70 Gy as an application of therapeutic
radiotherapy is within the frame of current health care.
The study is in line with the Declaration of Helsinki,
the laws and regulations of the country and in accord-
ance with good clinical practice (ICH Harmonized Tri-




The study sponsor for patients treated at the Department
of Radiation Oncology of the Charité Universitätsmedizin
Berlin, Germany is the Charité Universitätsmedizin Berlin,
Germany. The study sponsor for patients treated at the
Department of Radiation Oncology of the University
Hospital of Tuebingen is the University Hospital of
Tuebingen, Germany.
Results and discussion
This study will investigate the safety and feasibility of mod-
erately dose-escalated radiotherapy combined with regional
hyperthermia for patients with biochemical recurrence after
prostatectomy. The applied radiation technique, including
IMRT or rotational techniques, and thermometry
(MR-based thermometry is allowed) of hyperthermia
both represent the latest technical developments [37]. This
ensures that the study is performed at the highest technical
level and is essential to minimize potential modality-related
side-effects, since knowledge on radio-thermotherapy after
prostatectomy is limited [23].
All treatment optimization studies on sRT share the
same local risks. Treatment is given to the urethral anas-
tomosis where fibrosis, stenosis or, in the worst case, a
leakage could occur. With regard to the most technically
advanced randomized trial on postoperative radiotherapy
using 3D-conformal radiotherapy (3D-CRT) to the pros-
tatic fossa, the total dose of 60 Gy was associated with
only 0.3 % G3+ side effects (1/307) [38]. Goldin et al.
ascertained that there was no difference in toxicity between
IMRT and 3D-CRT in the postoperative setting [39]. It
might be speculated that this finding was based on the gen-
eral low frequency of side effects in this radiation dose
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higher radiation dose levels, IMRT was beneficial for
patients with definitive prostate radiotherapy. This was
demonstrated in a propensity score-adjusted analyses
(n = 12,976) of data from the Surveillance, Epidemiology,
and End Results (SEER) database [40]. The use of IMRT
compared with 3D-CRT was associated with less gastro-
intestinal morbidity and fewer hip fractures, but more
erectile dysfunction potentially caused by the higher total
dose in the IMRT group. The RTOG target volume defin-
ition [41] used in the Godin study was clearly larger com-
pared to the EORTC target volume definition. The larger
and more regular the treatment volume, the smaller the
benefit from IMRT. Consequently, findings from trials
using another target volume definition can only be applied
with caution.
The SAKK 09/10-study did not detect significant differ-
ences in CTCAE-measured acute toxicity between 64 Gy
and 70 Gy. Urinary quality of life was slightly but signifi-
cantly worsened in the higher dose group, independent of
radiation treatment technique [12]. Reduction of the high-
dose target volume in cases of clear identification of high
risk areas (modified boost concept) was reasonable and was
therefore introduced in this study. A first hint on efficacy of
radio-thermotherapy (secondary endpoint) could allow
comparison of this study with the SAKK 09/10 outcome
data, since target definition, cancer-related inclusion and
exclusion criteria were equal. A recently published retro-
spective study demonstrated a significant benefit for pa-
tients with positive margin but no macroscopic recurrence
treated to at least 70 Gy compared to a patient cohort with
a total dose of 66 Gy (100 % vs. 66.7 %) [42].
The RTOG 96–01 study demonstrated that sRT to
64.8 Gy and 2 years of ADT increased PSA-control (57 %
vs. 40 %) without any influence on overall or disease-
specific survival at 7 years [11]. However, long-term ADT is
associated with general side effects such as sarcopenia,
erectile dysfunction, fatigue and osteoporosis with a risk of
fractures [43]. Furthermore, there are hints that changes in
lipid metabolism could lead to a greater incidence of dia-
betes and cardiovascular disease, including renal complica-
tions [44–46]. Consequently, Ahmadi et al. concluded that
the best way of preventing side effects is to only use ADT
when it is absolutely indicated [43]. Cardiovascular mortal-
ity did not differ in otherwise healthy study participants of
8 randomized trials on long-term ADT [47]. However, the
influence of long-term-ADT in patients with pre-existing
co-morbidities remains unclear. Therefore, hyperthermia
could become a sRT optimization tool to circumvent long-
term ADTand its suspected side-effects.
Conclusion
The ongoing phase II study implements highly precise
image-guided radiotherapy and regional hyperthermia. Ifthe phase II study is found to be safe and feasible, a mul-
ticenter phase III study is planned to test whether the
addition of ten hyperthermia applications to dose-
intensified sRT improves biochemical control.
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